SYNMUE™ LP28 for Immune Aging
SYNMUE™ LP28 for Immune Aging
Immune Aging Starts Earlier Than You Think
After age 30, the body's immune responsiveness begins to change gradually. Natural Killer (NK) cells — the front-line defenders of the innate immune system — may become less responsive over time, leaving the body slower to react when it matters most.
This process is known as immunosenescence: not the disappearance of immunity, but its gradual dulling.
Age-related decline timeline
• Age 30+ — Immune responsiveness begins to decline
• Age 50+ — NK cell activity becomes increasingly important
• Age 65+ — Immune resilience becomes critical
What this means
Slower Response — NK cell responsiveness may gradually decline with age.
Reduced Resilience — Daily immune defense becomes less responsive over time.
Need for Daily Support — Proactive immune care becomes part of everyday wellness.
The Next Frontier in Healthy Aging
Healthy aging is one of the fastest-growing segments in the global nutraceutical market. Yet while brands compete in joints, muscle, metabolism, and cognition — immune aging remains a scientifically recognized but commercially unoccupied space.
The timing is now. As populations age globally, demand for proactive immune resilience solutions is accelerating.
Key market data
• Global immune health market valued at $35B+ (2024), projected to exceed $76B by 2033
• Global population aged 65+ will more than double to 1.6 billion by 2050 (UN)
• Taiwan officially entered super-aged society status in 2025
• China's population aged 60+ reached approximately 297 million in 2023
SYNMUE™: Wake Your Natural Killer
SYNMUE™ features Lactiplantibacillus plantarum LP28 — a patented probiotic strain developed by SynbioTech to support NK cell activity, strengthen first-line immune defense, and promote healthy aging resilience.
How SYNMUE™ Works
SYNMUE™ LP28 activates immune resilience through a three-step pathway:
1. Gut microbiome balance — LP28 supports a healthy gut environment, where 70% of the body's immune cells reside.
2. Gut–immune axis activation — A balanced gut stimulates immune signaling, supporting a responsive innate immune system.
3. NK cell activation — Immune signals travel systemically, raising NK cell cytotoxic activity and restoring front-line defense.
Clinical Evidence
Science-backed. Human-tested.
A 12-week randomized, double-blind, placebo-controlled study in 96 healthy adults aged 50–75.
Key findings
• NK cell cytotoxic activity significantly increased in the LP28 group, with effects sustained through week 12
• Favorable changes observed in immune biomarkers, including increased IL-12 and reduced CRP
• Substantially lower incidence of common colds in the LP28 group compared to placebo
Daily dosage: 10B CFU/day
Flexible for Any Brand
SYNMUE™ LP28 is clinically validated probiotic ingredient, ready to integrate into a wide range of product formats. Brand partners can build differentiated immune aging solutions for their target consumers.
Product formats
• Powder
• Sachet
• Capsule
Consumer moments
SYNMUE™ connects clinical science to everyday consumer needs:
• Season changes — proactive daily defense year-round
• High-stress periods — immune resilience when the body needs it most
• Travel — sustained front-line protection across environments
• Healthy aging — addressing a genuinely felt concern for adults 50+
Why SynbioTech?
• Strain Discovery & Culture Bank
• Manufacturing & Quality Assurance
• Clinical Validation Support
• One-Stop Customized Solutions
Let's Build Something Together
Let's discuss how SYNMUE™ can differentiate your immune defense, healthy aging, and daily resilience portfolio.